The laboratory diagnosis of heparin-induced thrombocytopenia (HIT) is based on an enzyme immunoassay combined with a functional test, and serotonin release assay (SRA) is the gold standard for detecting activating HIT antibodies. However, a recent atypical history of HIT prompted us to evaluate whether addition of platelet factor 4 (PF4) during SRA could improve its ability to detect pathogenic HIT antibodies. Using 5B9, a monoclonal antibody to PF4/H with a human Fc fragment, we first defined the optimal PF4 concentration for detecting low amounts of platelet-activating IgG with SRA. Plasma samples from 50 patients with suspected HIT were then studied, and SRA was positive in 17 cases (Group SRA pos ), with relatively high levels of PF4-specific IgG (median optical density = 2Á66). SRA was also systematically performed after adding 10 lg/ml of PF4 in the reaction mixture, and significant serotonin release was measured with samples from 9 additional patients (Group PF4-SRA pos ). Importantly, levels of PF4-specific IgG were similar in these samples and those from the 24 persistently SRA negative patients. Moreover, the pre-test probability of HIT was intermediate/high in all 'SRA pos ' or 'SRA-PF4 pos ' patients. In conclusion, addition of exogenous PF4 might improve the detection of pathogenic HIT antibodies by SRA.
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Heparin-induced thrombocytopenia (HIT) is a rare but lifethreatening complication of heparin treatments, with venous or arterial thrombosis seen in almost 50% of patients (Warkentin & Kelton, 1996) . HIT is due to the development of antibodies against platelet factor 4 (PF4) modified by heparin (Amiral et al, 1992) , which bind Fcc receptors (FccR) on blood cells via their Fc fragment (Brandt et al, 1995) (Rollin et al, 2016) , and induce multicellular activation with hypercoagulability and high risk of thrombotic complications. With the multiplicity of HIT features and the fact that only a subset of anti-PF4/heparin antibodies is truly pathogenic (Warkentin et al, 2005) , the diagnosis of HIT is often challenging. This diagnosis should be based on the occurrence of one or more HIT-associated clinical events and the demonstration in many patients that specific antibodies activating platelets are present in serum or plasma (Arepally & Ortel, 2010) . Clinical probability scores, such as the 4Ts (thrombocytopenia, timing of platelet count fall, thrombosis or other sequelae, other causes for thrombocytopenia) score, combined with rapid immunoassays are validated approaches to rapidly exclude HIT (Pouplard et al, 2007) (Leroux et al, 2014) , but despite high clinical probability and/or positive rapid-immunoassay results, enzyme-linked immunosorbent assay (ELISA) should always be performed to detect PF4-dependent antibodies (Lubenow et al, 2010) (Warkentin, 2011) . Most pathogenic antibodies are of the IgG class, and immunoassays specific for IgG are highly recommended because of their good sensitivity and better specificity than polyspecific assays . However, the positive predictive value of ELISA remains weak (Lo et al, 2007; Husseinzadeh et al, 2017) , although a correlation has been demonstrated between ELISA optical density (OD) and the probability of pathogenic antibodies (Warkentin et al, 2008) . The diagnostic accuracy of HIT can be optimized by combining anti-PF4/heparin ELISA with a functional platelet activation assay identifying anti-PF4/heparin IgG antibodies able to activate platelets from healthy donors in the presence of therapeutic heparin concentrations.
Platelet activation assays can be performed with plateletrich plasma (PRP) or washed platelets (WP). However, a platelet aggregation test (PAT) performed with PRP may yield false negative results, with low sensitivity ranging from 39% to 81% (Chong et al, 1993) . Platelet activation assays with WP i.e., serotonin release assay [SRA] and heparin-induced platelet activation [HIPA] are more sensitive and specific, and therefore preferable.
For many years, SRA has been considered the gold standard for the diagnosis of HIT because of its reported excellent specificity (> 99%) and good sensitivity (over than 95%) (Sheridan et al, 1986) . Nevertheless, this evaluation must be nuanced because reference standards against which to measure SRA performances do not exist (Cuker, 2014) . In this way, we were recently confronted with a case of atypical history of clinical and biological HIT, which prompted us to evaluate whether the addition of exogenous PF4 in the reaction mixture might improve the assay's performance.
Patients and methods

Patients with suspected HIT
The first patient prompting this study was a 74-year-old man hospitalized in Lille (France) for myeloma and who received unfractionated heparin (UFH) for right atrium thrombosis (index case). Thrombocytopenia and pulmonary embolism occurred within the first day of heparin treatment, and earlyonset HIT was suspected. Unfractionated heparin was replaced with danaparo€ ıd sodium, and platelet count was corrected within 3 days (Fig 1A) . Laboratory tests revealed significant levels of IgG antibodies to PF4/heparin (OD 1Á2) with a clearly positive PAT ( Fig 1B) . As the clinical history was atypical, a plasma sample was sent to our laboratory and SRA was performed to confirm the diagnosis of early-onset HIT, but results were surprisingly negative after testing platelets from two different donors (Fig 1C) . Because PAT is performed with PRP and SRA with WP, we hypothesized that PF4 concentration on cell surfaces might be too low for heparin-dependent platelet activation when this patient's sample was tested by SRA. Therefore, we evaluated whether the addition of exogenous PF4 was beneficial for platelet activation induced by PF4/heparin antibodies when evaluated by SRA. Thus, plasma samples from 50 other patients with clinically suspected HIT were also studied. Clinical and laboratory information was obtained regarding thrombocytopenia, thrombosis, bleeding, other causes of thrombocytopenia, alternative anticoagulation and platelet count evolution before and after the discontinuation of heparin. The probability of HIT was assessed by the updated 4Ts pre-test score (Linkins et al, 2012) , obtained by two independent evaluators and submitted to another expert in case of discrepancy.
According to the 4Ts score, patients were classified in three groups corresponding to low, moderate or high pre-test probability of HIT. When HIT was suspected after cardiac surgery with cardiopulmonary bypass, the 4Ts score was not obtained because the post-operative platelet count (PC) profile was more reliable for evaluating the likelihood of HIT in this clinical situation (Pouplard et al, 2005; .
Levels of PF4-specific IgG antibodies were detected in all cases by ELISA (HAT-45G â Life Code; Immucor, Paris, France) according to the manufacturer's instructions, and SRAs were performed without (SRA) and with PF4 (PF4-SRA).
Serotonin release assays
The measurement of the percentage release of serotonin, a normal component of platelet dense granules, has been used for many years to quantify the magnitude of platelet activation induced by HIT antibodies. In this study, all samples were evaluated by using the conventional SRA procedure and a modified assay based on the presence of additional PF4 in the platelet buffer.
Conventional SRA was performed as previously described (Sheridan et al, 1986 ) with minor modifications. Platelets from healthy donors were selected according to their good responsiveness to known HIT plasma samples, and labelled with 14 C-serotonin ( 14 C-5HT, Perkin Elmer, Villebon-surYvette, France) for 45 min at 37°C (14Á8 kBq/ml PRP). After washing, 75 ll of labelled platelets suspended at 300 9 10 9 /l in Tyrode buffer with calcium 3 mmol/l were incubated for 1 h at room temperature with 20 ll tested sample and 5 ll unfractionated heparin at 0, 0Á1, 0Á5 or 10 iu/ml (final concentrations). The release reaction was terminated with PBS-EDTA (0Á1 mol/l) and platelets were then centrifuged. The radioactivity in the supernatants was then counted by Liquid Scintillation Counting (LSC; Perkin Elmer) and expressed as percentage release of serotonin (%) by comparison with the total radioactivity in the platelet preparation. PF4-modified SRA (PF4-SRA) was then developed to assess the effect of exogenous human PF4 (Hyphen BioMed, Neuville-sur-Oise, France) on platelet activation induced by HIT antibodies. First, we evaluated the effect in SRA of increasing concentrations of a monoclonal HIT antibody (5B9; 1, 2Á5, 5, 10 and 20 lg/ml) in the presence of various amounts of PF4 (2Á5, 5 and 10 lg/ml). 5B9 is a monoclonal chimeric anti-PF4/heparin IgG1 antibody with a human constant fragment that perfectly mimics the effects of human pathogenic HIT antibodies (Rollin et al, 2015) . PF4 was systematically pre-incubated for 10 min with platelets before testing, to allow interaction with the cell surface.
The PF4 concentration that enabled positive SRA results in the presence of the lowest 5B9 concentrations was then selected for further experiments with plasma samples from patients with suspected HIT. In addition, plasma samples from 7 patients that had previously been tested positive with conventional SRA were diluted (1/10, 1/20, 1/40) and tested again with SRA and PF4-SRA.
Whatever the assay performed (conventional SRA or PF4-SRA), a test result was defined as positive with 14 C-serotonin release ≥ 20% measured at 0, 0Á1 or 0Á5 iu/ml with complete inhibition at 10 iu/ml. A test result was defined as negative if the release was < 20% or not inhibited in the presence of 10 iu/ml UFH.
Statistical analysis
Statistical analyses were performed using GraphPad Prism. A P value < 0Á05 was considered statistically significant. Pairedt test, Mann-Whitney test with Gaussian approximation and Fisher's exact test were chosen to compare mean serotonin release, median anti-PF4 antibodies titres, and occurrence of thrombotic events between patients groups respectively.
Results
Exogenous PF4 sensitizes heparin-dependent platelet activation induced by 5B9 on SRA
The effect of various concentrations of 5B9 was first evaluated by SRA without the addition of PF4. As expected, positive results with typical platelet activation patterns were obtained with the highest 5B9 concentrations (20 and 10 lg/ ml) tested with UFH at 0Á1 iu/ml, with maximal serotonin release values of 47% and 40%, respectively. When lower 5B9 antibody concentrations were tested (1 and 2Á5 lg/ml), the serotonin release markedly decreased and was lower than 20% with 2Á5 and 1 lg/ml, regardless of UFH concentration (Fig 2A) .
When 10 lg/ml PF4 was added to the platelet buffer, these low concentrations of 5B9 induced significant serotonin release with 0Á1 iu/ml UFH (maximal values of 33% and 39% with 1 and 2Á5 lg/ml 5B9, respectively; Figure 2B and C). The strongest serotonin release was measured with UFH 0Á5 iu/ml rather than 0Á1 iu/ml when 10 and 20 lg/ml 5B9 were tested with exogenous PF4 (Fig 2D for 20 lg/ml 5B9; data not shown for 10 lg/ml 5B9).
Exogenous PF4 improves the sensitivity of SRA to detect heparin-dependent platelet-activating antibodies in patients with suspected HIT From the results obtained with 5B9, subsequent experiments were systematically performed without (SRA) and with 10 lg/ml exogenous PF4 (PF4-SRA) in the same run.
First, PF4-SRA performed with plasma from the index case showed strong serotonin release (64%), evidenced in the presence of 0Á5 iu/ml UFH, which was fully inhibited with 10 iu/ml UFH. This result confirmed the presence of potentially pathogenic HIT antibodies in the sample (Fig 1C) .
Samples collected from 50 other patients with suspected HIT were then tested without additional PF4, and SRA was positive in 17 cases (SRA pos group) with a mean maximal serotonin release of 46% at 0Á1 iu/ml UFH (range: 23-85%) (Fig 3A, C) . When PF4 (10 lg/ml) was added to the platelet buffer, heparindependent platelet activation with typical pattern and mean maximal serotonin release of 39% at 0Á5 iu/ml UFH (range: 29-54%) was evidenced in an additional 9 samples (PF4-SRA pos group) (Fig 3B, C) . Whatever the incubation conditions (with or without PF4), this release was always inhibited with UFH 10 iu/ml, which supports the presence of HIT antibodies. Serotonin release assay performed in the presence of additional PF4 remained negative in the 24 other cases (PF4-SRA neg group) (Fig 3B) . On the other hand, the pattern of platelet activation was different with samples from the SRA pos group, with stronger serotonin release without heparin in the presence of 10 lg/ml PF4 (47% vs. 21% with and without PF4, respectively, P = 0Á0005; n = 17) (Fig 3A and  B) . SRA, almost 90% of them (15/17) activated platelets without heparin when PF4 was present (Fig 3D) . In contrast, only 2 of 9 PF4-SRA pos samples (22%) slightly activated platelets in the same conditions. In addition, levels of IgG antibodies specific to PF4 were similar in PF4-SRA pos samples and the 24 samples for which PF4-SRA remained negative (median OD: 1Á6; range: 0Á78-3Á00 vs. median OD: 1Á3; range: 0Á63-2Á59 respectively; P = 0Á38). In contrast, plasma samples yielding a positive result in SRA without PF4 had higher levels of PF4-specific IgG antibodies (median OD: 2Á7; range: 0Á78-3Á00; P = 0Á03 compared with PF4-SRA pos group and P < 0Á0001 with PF4-SRA neg group) (Fig 4A) .
Plasma samples from 7 selected positive patients were further tested in SRA after dilution (1/10, 1/20, 1/40) with and without 10 lg/ml PF4. Conventional SRA was negative with diluted plasma samples, but the addition of PF4 enabled the detection of lower levels of activating HIT antibodies (Fig 4B) , in accordance with the preliminary results obtained with 5B9.
The 4Ts pre-test probability score obtained with 40 patients was high, intermediate and low for 12, 20 and 7 cases, respectively (Table I) . HIT had been suspected after cardiac surgery in the 11 remaining cases based on the evolution of platelet count post-operatively, and the 4Ts score was not obtained. Conventional SRA (i.e., without PF4) was positive for 4 of these patients and a significant serotonin release was also measured in 3 additional cases after the addition of PF4.
Of note, the pre-test probability of HIT was intermediate or high for all SRA pos and PF4-SRA pos groups but was low in 29% of the PF4-SRA neg group. Heparin had been systematically replaced by a non-heparin anticoagulant in patients of the PF4-SRA pos group, with recovery of normal platelet count in all cases: this evolution is in agreement with HIT diagnosis.
Discussion
Serotonin release assay is considered the most specific functional test for demonstrating heparin-dependent platelet-activating antibodies in patients with suspected HIT. However, the sensitivity of SRA may sometimes be too low, particularly when plasma levels of IgG antibodies and/or PF4 are not high enough. This limitation of SRA performance was illustrated by the history of our patient suspected of having early-onset HIT: significant levels of PF4-specific antibodies were detected on ELISA, and PAT performed with PRP gave positive results. However, unexpectedly, the SRA results remained negative after testing 2 different donors, although this method is considered more sensitive and specific than PAT for detecting HIT antibodies. The variability of platelet response to PF4-specific IgG antibodies among donors has been reported for many years and is the reaseon why testing PRP from at least 5 donors is recommended when performing PAT for the diagnosis of HIT (Chong et al, 1993) . No specific recommendation was proposed for the number of donors to be tested in SRA, even though marked variability in platelet response to HIT sera has been shown among donors (Warkentin et al, 1992 ) . Gene polymorphisms affecting the binding of HIT IgG-PF4-heparin complexes to FccRIIa receptors or subsequent platelet signalling and activation may contribute to this variable response (Rollin et al, 2012 (Rollin et al, , 2015 . However, we hypothesized that the amount of PF4 on the platelet membrane was also a critical factor, particularly when testing washed platelets and as supported by our study. Indeed, the addition of 10 lg/ml PF4 to the platelet buffer allowed for lower levels of 5B9 to activate platelets with heparin. In that way, when samples from suspected HIT patients were tested in SRA with additional PF4, a significant release was measured, with some previously tested as negative with the conventional assay. Interestingly, 15 of 17 plasma samples from SRA pos patients also induced platelet activation without Type of heparin administered = UFH, LMWH or both; clinical probability of HIT assessed in non-cardiac surgery patients using the 4Ts score. Patients who underwent cardiopulmonary bypass were not assessed for 4Ts score. HIT, heparin-induced thrombocytopenia; LMWH, low molecular weight heparin; NA, not assessed; PF4, platelet factor 4; SRA, serotonin release assay; UFH, unfractionated heparin.
exogenous heparin when PF4 was added. Noticeably, residual heparin was detected using a sensitive chromogenic assay in 8 of these samples (data not shown), probably contributing to this effect. Significant serotonin release was also induced without heparin in the presence of exogenous PF4 with 5B9 when tested at relatively high concentrations (i.e., 10 or 20 lg/ml). Using KKO, a murine monoclonal antibody specific to PF4-heparin complexes, Rauova et al (2006) were the first to show that heparin was not necessary for platelet binding of HIT antibodies when additional PF4 was present.
More recently, Padmanabhan et al (2015) demonstrated in SRA-positive samples that PF4 promoted HIT IgG binding on platelets without heparin. Warkentin and Kelton (2001) also described a subset of HIT antibodies that induced platelet activation without heparin nor PF4 (Warkentin & Kelton, 2001) , which were particularly pathogenic, being associated with deeper thrombocytopenia, delayed platelet count recovery and more frequent clinical complications (Linkins & Warkentin, 2011) . In our study, a similar SRA pattern was evidenced for 5 SRA pos patients, including 4 in whom no residual heparin could be detected, all having high clinical probability of HIT (4Ts score ≥ 6 or biphasic PC evolution after CPB) with thrombotic complications in 4 cases. PF4 is a cationic protein with a positive ring that is critical for its interaction with negatively charged molecules, including heparin (Zhang et al, 1994) or glycosaminoglycans (GAG) and may bind to various cells that expose proteoglycans, including platelets (Nader, 1991) . In this regard, PF4 released in vivo by activated platelets only transiently circulates in plasma and quickly binds GAG on cells (Rybak et al, 1989; Stringer & Gallagher, 1997) . Therefore, if present in sufficient amount, PF4 tetramers may form ultra-large complexes (ULC) with chondroitin 4 sulphate molecules on platelets (Rauova et al, 2005) , and heparin is no longer required for HIT IgG platelet binding and activation. In support of this concept, platelet treatment with chondroitinase ABC was recently found to reduce PF4-dependent HIT IgG binding (Padmanabhan et al, 2015) .
Recently, Padmanabhan et al designed an assay in which platelet activation by HIT antibodies was assessed by evaluating P-selection expression on platelet surface using flow cytometry (PEA) (Padmanabhan et al, 2015) . Pre-incubation of platelets with PF4 sensitized the detection of HIT activating antibodies in PEA and our results are in agreement with this finding (Padmanabhan et al, 2016) . Nazi et al (2015) also recently showed that exogenous PF4 led to positive SRA results with 36% of samples initially tested as negative with conventional SRA. However, patients with positive PF4-SRA results had low clinical probability of HIT and no thrombosis, and the authors assumed that PF4-SRA lacked specificity and therefore could lead to HIT overdiagnosis by detecting sub-threshold levels of pathogenic antibodies . In our study, all patients in the PF4-SRA pos group had intermediate or high 4Ts score, and 4 experienced thromboses. In addition, the platelet count recovered to a normal value after heparin withdrawal in all these cases; therefore, we considered that a positive PF4-SRA result combined with significant levels of PF4-specific IgG, favoured HIT. Of note, we used a 5 times lower concentration of PF4 (10 lg/ml) than chosen by Nazi et al (50 lg/ml), as this enabled the lowest concentrations of 5B9 to be detected by SRA. Moreover, the concentration of 10 lg/ml was close to those measured in serum (Brandt et al, 2000) or in PRP stimulated with HIT IgG and heparin (Newman & Chong, 2000) , i.e. 3-15 or 5 lg/ml, respectively. Hence, very high levels of exogenous PF4 may reduce the specificity of PF4-SRA, as suggested by Nazi et al (2015) , whereas lower concentrations could help detect antibodies with real clinical significance.
Titres of HIT IgG, evaluated by immunoassays, strongly predict a positive SRA result (Warkentin, 2012) . Nevertheless, in our study, similar levels of PF4-specific IgG antibodies were measured in PF4-SRA pos and PF4-SRA neg groups, and thus PF4-SRA results were not exclusively dependent on antibody titres. Several PF4 regions have been recently identified by crystallographic studies to be critical in HIT pathophysiology (Cai et al, 2015) , and PF4-SRA might detect other PF4 epitopes with variable affinity for antibodies to PF4-heparin complexes.
In conclusion, PF4-SRA appears to sensitize the detection of low levels of pathogenic HIT antibodies and might be helpful in the laboratory diagnosis of HIT. However, larger studies are needed to confirm the beneficial effect of exogenous PF4 on SRA performance.
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